Thalidomide enhances rituximab-mediated antibody dependent cell mediated cytotoxicity. We therefore conducted a phase II study using thalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naïve to either agent.
Introduction
Monoclonal antibodies have been successfully used to treat patients with B-cell malignancies, including Waldenstrom's macroglobulinemia (WM). Most of these efforts have focused on the use of rituximab, a chimeric human IgG 1 monoclonal antibody which targets CD20 which is widely expressed in WM 1, 2 . Studies employing standard dose rituximab therapy have demonstrated activity in WM, with overall response rates of 27-35% and median durations of response from 8 to 27+ months [2] [3] [4] [5] [6] [7] . More recently, the use of were observed in these studies, with median durations of response from 16+ to 29+ months 8, 9 . Among WM patients receiving rituximab as monotherapy, lower response rates have been observed in those patients with high serum IgM (>6,000 mg/dL) and beta-2 microglobulin (B 2 M) (>3.0 mg/L) levels, as well as homozygous expression of phenylalanine at amino acid position 158 on CD16 (FcγRIIIA-158) [8] [9] [10] .
Studies combining rituximab with chemotherapy have also been explored in WM 11 . The combination of nucleoside analogues plus rituximab has yielded major response rates of 70-90% [12] [13] [14] [15] , whilst the combinations of CHOP-R (cyclophosphamide, adriamycin, vincristine, prednisone, rituximab) or DC-R (dexamethasone, cyclophosphamide,
For personal use only. at Harvard Libraries on November 7, 2008 . www.bloodjournal.org From rituximab) have resulted in response rates of 80-90% [16] [17] [18] . Median time to progression in excess of 3 years has been reported with these combinations. Whilst the above combinations have produced more impressive responses, greater toxicity has also been reported in WM patients, with the use of nucleoside analogues causing prolonged neutropenia, stem cell damage, disease transformation, and secondary myelodysplasia/acute leukemia 11, 12, 19 .
In an effort to augment monoclonal antibody responses in WM patients whilst averting short and long term chemotherapy-induced toxicities, we have sought the development of immunomodulatory agents for combination therapy with rituximab. Thalidomide is an immunomodulatory agent which induces the elaboration of immunostimulatory cytokines, including interleukin-2 and interferon-γ 20 . Importantly, thalidomide induces the expansion of natural killer (NK) cells which are important effectors of in vivo rituximab activity, as well as increased antibody dependent cell mediated cytotoxicity (ADCC) induced by rituximab [20] [21] [22] [23] [24] . As monotherapy, thalidomide has modest activity in WM patients, producing response rates of 25%, whilst the combination of thalidomide plus steroids and/or clarithromycin produces response rates of 40% [25] [26] [27] . In view of these considerations, we carried out a phase II study of thalidomide and rituximab and here present outcome and long term follow-up. 
Patients and Methods
Patients with a clinicopathological diagnosis of WM 28 , who were naïve to rituximab and thalidomide, who had CD20 positive disease as determined by previous bone marrow immunohistochemistry or flow cytometry, and who required therapy based on consensus guidelines 29 were eligible for this study. A monoclonal IgM protein, a minimum IgM level > 2 times the upper limit of normal, a baseline platelet count of > 25,000/uL, an absolute neutrophil count of > 500/uL, a serum creatinine of < 2.5 mg/dL (unless nephropathy was attributable to their WM), a serum total bilirubin and SGOT of < 2.5
times the upper limit of normal, and an ECOG performance status of 0-2 were required for entry. No chemotherapy, steroid therapy, or radiation therapy within 30 days of study entry was permitted. Patients who were pregnant or lactating, had serious co-morbid disease, had any uncontrolled bacterial, fungal or viral infection, or an active second malignancy were not eligible. All men and women of reproductive potential were required to agree to use an acceptable method of birth control before, and during treatment, as well as for six months after completion of study treatment, and be willing to comply with the FDA-mandated S.T.E.P.S. ® program.
All patients provided informed written consent in accordance with the Declaration of Helsinki, and the Dana Farber/Harvard Cancer Center institutional review board Using 80% power and alpha set at 0.05, eleven patients were to be included in the first stage of the two-stage design to test the null hypothesis that the probability of response is < 50% versus the alternative that probability of response > 75%. For the first stage, after Rituximab plus Thalidomide is administered to 11 patients, the study would have been terminated if 6 or fewer patients respond. If 7 or more patients responded in the first stage of the trial, an additional 14 patients were to be enrolled and treated during stage II. If, after study completion, the total number responding is greater than 16, the null hypothesis that Rituximab plus Thalidomide treatment produces a response rate less than 50% will be rejected.
Response determination
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Analysis of peripheral blood effector cells and FcγRIIIA polymorphisms
Serial changes in the absolute levels of peripheral blood effector cells and determination of FcγRIIIA-158 polymorphisms were performed as previously described 10, 18 .
Statistical analysis
Comparison of pre-and post-treatment parameters was performed using a two-tailed students t-test on Microsoft Excel™ software. 
Results

Patient and disease characteristics
The clinical features of the 25 patients enrolled in this study are summarized in Table 1 .
Of the 25 patients enrolled on study, 20 were previously untreated. Of the 5 previously treated patients, 4 (16%) and 1 (4%) of patients demonstrated relapsed disease or disease refractory to their prior therapy, respectively. Six (24%) of the 25 patients were documented by clinical history and/or examination to have grade 1 sensory neuropathy attributable to their WM at baseline. Anti-myelin associated glycoprotein (MAG) and anti-ganglioside M1 (GM1) antibody studies were obtained on these patients, of whom only one patient was positive for the anti-MAG antibody. The median cumulative dose of thalidomide administered for the intended 52 week treatment period among all enrolled patients was 19,950 mg (range 2,100 to 96,000 mg). Twenty-one and two patients completed 8 and 4 infusions of rituximab therapy, respectively, and therefore were evaluable for response. Both unevaluable patients died prior to completing the first 4 weeks of rituximab therapy due to events deemed unrelated to protocol therapy: (1) complications associated with chronic obstructive pulmonary disease; and (2) autoimmune myopathy and cardiomyopathy. The circumstances of both deaths on study were reviewed by the Drug and Safety Monitoring Board (DSMB), which deemed the events to be unrelated to protocol therapy. patients, including resolution in 2 patients, whereas in one patient the sensory neuropathy worsened. For responding patients, the median time to best response was 18.9 (range 3.8-41.4) months, and the median time for a 25% reduction in serum IgM among responders was 4.7 (range 0.7-24.0) months. Among major responders, the median time to achieving a 50% reduction in serum IgM was 7.9 (range 2.8-21.8) months, which was in line with our previous experience with extended rituximab monotherapy 8 .
For
Time to progression
The median time to progression for all evaluable patients was 34. 
Changes in hematological parameters
Pre-therapy, 6 (26.1%) and 2 (8.7%) of 23 evaluable patients demonstrated a hematocrit of <30% and a platelet count of <100,000/uL, respectively. Following therapy, and at best response, 1 (4.3%) and none of the 23 evaluable patients demonstrated a hematocrit of <30% and a platelet count of <100,000/uL, respectively. A significant increase in the median hematocrit was noted for the 23 evaluable patients, from 33.0% (range 23.6-42.6%) before to 37.6% (range 29.3-44.3%) following therapy (p=0.004). Pre-and posttherapy median platelet counts remained unaffected by therapy (p=0.73).
Toxicities
Dose reduction of thalidomide occurred in all patients and led to premature discontinuation in 14 patients. Discontinuation of thalidomide in these patients occurred at a median of 4.1 (range 1.2-10.4) months. Grade >2 toxicities were as follows: 
Paradoxical increases in serum IgM levels
Abrupt and paradoxical increases in serum IgM levels have been reported with the use of rituximab in patients with WM which can aggravate hyperviscosity and contribute to hyperviscosity-related symptoms 7, 30, 31 . For this reason, plasmapheresis was strongly encouraged for patients who had a pre-therapy serum viscosity of 3. IgM levels using the cutoff of 6,000 mg/dL, which in previous studies served as a determinant for rituximab response in WM. The overall response rate for patients whose IgM was >6,000 mg/dL and <6,000 mg/dL were 4/6 (68%) and 14/18 (78%), respectively (p=1.0). Time to progression for patients with patients with >6,000 mg/dL and <6,000
For personal use only. at Harvard Libraries on November 7, 2008. www.bloodjournal.org From mg/dL was 44.4 and 25.0 months, respectively (p=0.47). Lastly, we analyzed the impact of B 2 M levels on response parameters, given the prognostic significance of this variable in predicting overall survival in WM. Eight of 9 (89%) and 10/14 (71%) patients with a B 2 M level of >3 g/dL and <3 g/dL, respectively, responded to therapy (p=0.61). Time to progression between these subgroups did not differ significantly at 37.6 and 24.1 months, respectively (p=0.32).
For . Given these considerations, we focused our efforts on enhancing rituximab efficacy using agents which augment ADCC activity. In our preclinical studies, thalidomide and its analogue lenalidomide enhanced ADCC activity to rituximab, as well as the CD40 directed SGN-40 monoclonal antibody 24 . Moreover, in patients receiving thalidomide, increases were noted in circulating NK cells which is particularly important given their prominence as key effectors in patients treated with rituximab. Here, we carried out a clinical trial examining the activity of combination thalidomide and rituximab.
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The results of this study demonstrate a high overall (72%) and major response rate (64%) to combination thalidomide and rituximab therapy in WM patients. These results appear to be better than the major response rate reported with either rituximab (40-44%) or thalidomide (25%) monotherapy. Importantly, the responses in this study were durable and in excess of 3 years. The overall response rate and duration of response for thalidomide and rituximab appear on par with other active cytotoxic agent combination therapies employed in WM. Hence, the use of thalidomide and rituximab appears quite appealing as an alternative upfront therapy in WM, given the avoidance of cytotoxic chemotherapy and its stem cell sparing approach.
An important observation in this study was the dose limiting toxicities including neuropathies which necessitated reduction/and or discontinuation of thalidomide in most patients. The dose and schedule of thalidomide should therefore be the subject of further investigation, since lower start doses (< 200 mg daily), altered delivery schedule (i.e. 5 days per week), and more prolonged treatment beyond one year may yield more optimal results. It is interesting, however, that several important predictors of rituximab response (FcγRIIIA-158 polymorphism status, serum IgM and B 2 M levels) were negated in this study with the combination of thalidomide and rituximab. Further studies in larger patient cohorts will be required to confirm these findings since the patient numbers in this series may have contributed to the lack of significance for these variables.
The combination of thalidomide and rituximab did not appear to negate the paradoxical increases in serum IgM levels observed with the use of rituximab in patients with WM. In For personal use only. at Harvard Libraries on November 7, 2008. www.bloodjournal.org From this study, we observed that 30% of patients who were not pheresed prior to initation of the first course of rituximab treatment had a > 25% increase in serum IgM levels, which is on par with that previously reported by us and others 7, 31, 32 . Importantly, however, only 5% of the patients receiving the second course of rituximab had a spike of > 25% in serum IgM levels which may reflect the interim response to therapy for many patients.
Therefore, close monitoring of serum IgM levels, and symptomatic hyperviscosity should be maintained in patients treated with thalidomide and rituximab, and empiric plasmapheresis considered for patients with elevated serum IgM levels. Accordingly, the use of thalidomide plus rituximab should not be used in patients in whom a rapid decrease in serum IgM levels is required. In such patients other options can be considered, including the use of cytotoxic agent or bortezomib based therapy 35 .
Lastly, the use of the thalidomide analogue lenalidomide has become increasingly adopted given its higher response rates and fewer non-hematological toxicities in patients with multiple myeloma, as well as other B-cell disorders. We explored its use in combination with rituximab and observed higher ADCC activity in preliminary studies 24 .
However, its use in WM patients appears to be problematic due to the development of acute non-hemolytic anemia, signifying potential idiopathic toxicity for WM patients with this agent. Moreover, the response durations among patients who tolerated combined lenalidomide and rituximab were shorter than in this study 36, 37 . The reason for these discordant findings, particularly since lenalidomide is a more potent immunomodulating agent, remains speculative, but may ultimately involve other activities present in thalidomide but not lenalidomide which benefit WM patients, such as 
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